Navigation Links
Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
Date:1/3/2008

BEDFORD, Ohio, Jan. 3 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., announced the acquisition of CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution from Mead Johnson & Company. Bedford Laboratories is now the reference listed drug holder. CAFCIT(R) (caffeine citrate) is indicated for the short term treatment of apnea in premature infants between 28 and <33 weeks gestational age.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

"The acquisition of CAFCIT(R) demonstrates our continued commitment to build the most comprehensive and cost effective line of injectable products in the pharmaceutical industry. We are proud to offer a branded product at a generic price," said David Gaugh, Vice President and General Manager of Bedford Laboratories.

Bedford Laboratories will supply latex free CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution as a sterile liquid in the following presentations:

-- Injection: 60 mg/3 mL single-use vials individually boxed

-- Oral Solution: 60 mg/3 mL single-use vials, 10 vials per child-

resistant container

Prescribing information is available upon request from the Bedford Laboratories' professional services department, (800) 521-5169, or from the company's web site, http://www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and international markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim <
'/>"/>

SOURCE Bedford Laboratories
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Alma Lasers Announces Proposed Initial Public Offering
2. Smart Balance Announces Conversion of Convertible Preferred Stock
3. IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
4. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
5. Heska Announces Amended Agreement With AgriLabs
6. Versus Technology Announces Fourth Quarter Results
7. FASgen Announces New Research Discoveries in Lung Cancer
8. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
9. KV Pharmaceutical Company Announces NYSE Listing Extension
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
11. Transition Therapeutics Announces Appointment of Vice-President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Seven-year-old Riley Salz ... from autism. He receives 40 hours a week of ... shadowing) from the Center for Autism and Related Disorders ... August, 2008, and has experienced remarkable progress, including learning ... his environment. Riley’s personal journey through autism is now ...
(Date:6/18/2013)... has shown that cancer cells have a much different ... Now, scientists at The University of Texas at Dallas ... new strategy to combat lung cancer. , In an ... PLOS ONE , UT Dallas researchers compared the metabolic ... cells taken from the same patient. , They ...
(Date:6/18/2013)... new commercial venture, using technology developed at Case ... and Case School of Engineering, has made available ... allows graduate students and others training to evaluate ... program, reducing stress on the trainee, because a ... real person. , Graduate students studying to ...
(Date:6/18/2013)... More than 1.1 million people in the U.S. ... the Centers for Disease Control and Prevention (CDC). Of those, ... of National HIV Testing Day on June 27, Allsup, a ... representation, the CDC and other organizations are raising awareness of ... about 50,000 new HIV infections each year. Along with developing ...
(Date:6/18/2013)... The Elizabeth Glaser Pediatric AIDS Foundation (EGPAF) joined ... Emergency Plan for AIDS Relief (PEPFAR) to mark PEPFAR’s ... the global effort to eliminate pediatric HIV/AIDs. U.S. ... June 2013, one million babies globally have been born ... in 2003, EGPAF has been a key implementer of ...
Breaking Medicine News(10 mins):Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 2Health News:June's Release of CARD's "Mission Possible: Portraits of Hope" Features Southern California Child and His Remarkable Progress with Intensive Autism Therapy 3Health News:UT Dallas study suggests new approach to fight lung cancer 2Health News:UT Dallas study suggests new approach to fight lung cancer 3Health News:SimuCase avatars advance speech-language pathology training 2Health News:Allsup Observes National HIV Testing Day June 27 2Health News:Allsup Observes National HIV Testing Day June 27 3Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 2Health News:One Million Babies Born HIV-free Signals Major Milestone in Global Effort to Eliminate Pediatric AIDS 3
... 24, 2011 Researchers at Memorial Sloan-Kettering Cancer Center have ... as PSA velocity is a poor predictor of prostate ... study of more than 5,000 men was published online February ... . Andrew Vickers, PhD, Associate Attending Research Methodologist in the ...
... Higher Education (AGHE) the educational branch of ... 37th Annual Meeting and Educational Leadership Conference from ... Plaza in Cincinnati, OH. Media representatives are invited ... a forum for professionals in the field of aging to ...
... , THURSDAY, Feb. 24 (HealthDay News) -- Fewer men ... (PSA) screening for prostate cancer since the release of guidelines ... few years ago, say researchers. This study examined ... decline in PSA screening was three percent among men aged ...
... University of Maryland-led team of scientists indicate that a ... antibody or a scorpion anti-malarial toxin could be ... combating malaria, at a time when the effectiveness of ... a study published in the February 25 issue of ...
... The U.S. Food and Drug Administration and Georgetown University ... stimulate innovation in regulatory science, ethics, education, and training. ... meet their common goal of improving public health. ... unique opportunities for supporting our goal of translating basic ...
... HealthDay Reporter , THURSDAY, Feb. 24 (HealthDay News) -- ... HIV patients and may stave off progression of the AIDS-causing ... for this purpose, the findings of this small study raise ... adjust the immune response in HIV patients whether they,re taking ...
Cached Medicine News:Health News:Change in PSA level does not predict prostate cancer 2Health News:As America's senior population grows, meeting to outline effective education about aging 2Health News:PSA Screening for Prostate Cancer Dips in Large U.S. Health Network 2Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 2Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 3Health News:New study shows ability of transgenic fungi to combat malaria and other bug-borne diseases 4Health News:FDA and Georgetown University Medical Center announce partnership 2Health News:Statins Might Help HIV Patients, Study Suggests 2
(Date:6/18/2013)... DENVER , June 18, 2013  Healthgrades, ... evaluate, compare and connect with physicians and hospitals, ... 2013: "Lean in" When Making Healthcare Decisions to ... the best performing hospitals for maternity care, gynecologic ... the treatment of women across 15 of the ...
(Date:6/18/2013)... RIDGE, N.J. , June 18, 2013  Pro ... Adrian Peterson and professional family expert Jo ... partnering with Mylan Specialty L.P., the fully integrated specialty ... ), to raise awareness of this significant health problem. ... the U.S. Food and Drug Administration (FDA) approval of ...
(Date:6/17/2013)... 17, 2013 Vanda Pharmaceuticals Inc. (Vanda) ... today at ENDO 2013, the Endocrine Society,s 95 ... entrain (synchronize) both melatonin and cortisol rhythms. This ... master body clock and address the circadian desynchrony ... SET (Safety and Efficacy of Tasimelteon) and RESET ...
Breaking Medicine Technology:Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 2Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 3Healthgrades Recognizes Top Hospitals in Treatment of Maternity Care, Gynecologic Surgery and Women's Health 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 2Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 3Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 4Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 5Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 6Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 7Mylan Specialty L.P. Joins Forces with Adrian Peterson and Jo Frost to Launch Anaphylaxis Preparedness Campaign 8Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 2Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 3Vanda Presents Data From Phase III Studies that Demonstrate Tasimelteon Restores Daily Cortisol Rhythm In Blind Patients With Non-24-Hour Disorder 4
... 2007 - Cytogen,Corporation (NASDAQ: CYTO) today reported ... 2007 Annual Meeting of the American,Association for ... Angeles,California April 14-18, 2007. The AACR abstracts ... approaches to drug,discovery and development embodied in ...
... DIEGO, March 29, 2007 /PRNewswire-FirstCall/ -- ... and,development company focused on commercializing proprietary ... and infectious diseases,announced today that results ... combination with intravenous 5-fluorouracil (5-FU),and capecitabine ...
Cached Medicine Technology:Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 2Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 3Preclinical Data on Cytogen's Technology to be Reported at the AACR,Annual Meeting 4ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 2ADVENTRX to Present CoFactor Multiagent Therapy Data at AACR Annual,Meeting 3
Inquire...
Inquire...
... Anatomical Malar I Implants - Providing ... implant follows the contour of the zygoma ... prominence. Anatomical Malar II Implants - ... the surgeon with another augumentation option that ...
... - Anatomically designed to enhance the chin contour, ... mandible with a high-profile central chin projection. ... entire mandible, this implant provides a high central ... arms. Cleft Chin Implants - Designed with ...
Medicine Products: